NASDAQ · Health Information Services · USD
Omnicell, Inc. (OMCL) Stock Analysis
Omnicell, Inc. (OMCL) is a Health Information Services stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
OMCL Key Statistics
As of Oct 21, 2026Trading
- Open
- $36.07
- Previous Close
- $36.49
- Day's Range
- 35.59–37.21
- 52-Week Range
- 29.09–55.00
- Volume
- 459.09K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.99
Valuation
- Market Cap
- $1.65B
- P/E Ratio
- 43.26
- Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
- 17.68
- PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
- 15.40
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 1.33
- EPS (ttm)Profit attributable to each share over the last twelve months.
- 0.84
Financials (FY)
- Revenue (FY)
- $1.18B+6.53%
- Net Income (FY)
- $2.05M−83.62%
- Profit marginThe share of revenue left as profit after all costs and taxes.
- 3.14%
- Shares Outstanding
- 45.48M
- 1-Year Return
- +17.30%
Dividend and dates
- Earnings Date
- October 29, 2026
- Avg Volume
- 639.19K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, OMCL closed at $36.34, +17.30% over 1 year.
Omnicell, Inc. (OMCL) has a market capitalization of $1.65B.
In fiscal 2025, OMCL reported revenue of $1.18B.
OMCL Stock Return by Calendar Year
Omnicell, Inc. (OMCL) 10-year return: what $10,000 became
- 1 year
- $10,000 $11,730
- +17.30%
- 5 years
- $10,000 $2,175
- −78.25%
- 10 years
- $10,000 $10,237
- +2.37%
If you had invested $10,000 in Omnicell, Inc. (OMCL) 10 years ago, at the close on October 21, 2016, it would have been worth $10,237 at the close on October 21, 2026: +2.37% in total, +0.23% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −19.78% |
| 2025 | +1.75% |
| 2024 | +18.31% |
| 2023 | −25.37% |
| 2022 | −72.06% |
| 2021 | +50.34% |
| 2020 | +46.87% |
| 2019 | +33.44% |
| 2018 | +26.27% |
| 2017 | +43.07% |
| 2016 (partial year) | −10.95% |
As of October 21, 2026.
OMCL Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $1.18B | $2.05M | 0.2% |
| 2024 | $1.11B | $12.53M | 1.1% |
| 2023 | $1.15B | −$20.37M | −1.8% |
| 2022 | $1.30B | $5.65M | 0.4% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $1.18B | $503.44M | $5.16M | $2.05M | 0.2% |
| 2024 | $1.11B | $471.00M | $337.00K | $12.53M | 1.1% |
| 2023 | $1.15B | $496.84M | −$34.87M | −$20.37M | −1.8% |
| 2022 | $1.30B | $588.99M | −$2.32M | $5.65M | 0.4% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
OMCL Valuation vs Health Information Services Median
Median of 44 stocks| Metric | OMCL | Health Information Services median | vs median |
|---|---|---|---|
| P/E | 43.26 | 46.54 | 7% below |
| P/S ratio | 1.33 | 2.31 | 43% below |
| Profit margin | 3.14% | −7.55% | 10.7 pts above |
Medians across 44 Health Information Services stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
Is This the Right Time to Retain Omnicell Stock in Your Portfolio?
YahooOmnicell to Release Third Quarter 2026 Financial Results on October 29, 2026
YahooDoes Omnicell’s Revenue Beat and Weak EBITDA Guidance Change The Bull Case For OMCL?
YahooHealthcare Technology for Providers Stocks Q2 Recap: Benchmarking Omnicell (NASDAQ:OMCL)
YahooOmnicell (OMCL) Stock Trades Below Fair Value After A 78% Slump
Yahoo3 Reasons OMCL is Risky and 1 Stock to Buy Instead
Yahoo
All 20 articles ↓Show fewer ↑
TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations
YahooOmnicell to Present at the Wells Fargo 21st Annual Healthcare Conference
YahooOmnicell: Offers Good Value, But Uncertainty Remains
SeekingAlphaOmnicell (OMCL) Is Down 12.5% After Raising 2026 Revenue Outlook And Returning To Profitability
YahooOmnicell (OMCL) Stock May Be 42% Below Fair Value On Weak Guidance
YahooPiper Sandler Reiterates Overweight on Omnicell, Lowers Price Target to $45
BenzingaWells Fargo Maintains Overweight on Omnicell, Lowers Price Target to $50
BenzingaKeybanc Maintains Overweight on Omnicell, Lowers Price Target to $65
BenzingaOmnicell, Inc. 2026 Q2 - Results - Earnings Call Presentation
SeekingAlphaOmnicell, Inc. (OMCL) Q2 2026 Earnings Call Transcript
SeekingAlphaOmnicell (NASDAQ:OMCL) Q2 Earnings Beat Overshadowed by Disappointing Guidance
ChartMillOmnicell Sees Q3 Adj EPS $0.35-$0.43 vs $0.47 Est; Sees Sales $301.000M-$307.000M vs $312.528M Est
BenzingaOmnicell Raises FY2026 Adj EPS Guidance from $1.80-$2.00 to $2.15-$2.30 vs $1.94 Est; Narrows FY2026 Sales Guidance from $1.215B-$1.255B to $1.225B-$1.245B vs $1.248B Est
BenzingaOmnicell Q2 Adj. EPS $0.94 Beats $0.47 Estimate, Sales $312.208M Beat $310.253M Estimate
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Health Information Services Stocks
Veeva Systems Inc.
$51.90B
BTSGBrightSpring Health Services, Inc.
$12.40B
TEMTempus AI, Inc.
$12.23B
HNGEHinge Health, Inc.
$9.04B
HQYHealthEquity, Inc.
$8.10B
DOCSDoximity, Inc.
$5.99B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B













